Ron Price - Accelerate Diagnostics President
| AXDX Stock | USD 1.64 0.03 1.80% |
President
Mr. Ron Price is Senior Vice President and Head of Commercial Operations, Americas of the Accelerate Diagnostics Inc. Mr. Price has served as Senior Vice President and Head of Commercial Operations, Americas since April 2015. Mr. Price has over 20 years of commercial operations experience and a proven track record of leading sales and marketing teams to achieve doubledigit revenue growth and strong bottomline performance. Prior to joining the Company, Mr. Price served as Vice President, Commercial Operations for Roche Point of Care managing all commercial responsibilities across three separate product lifecycles. In addition, Mr. Price held a number of sales, marketing, and leadership roles with Ventana Medical Systems from 2001 to 2012 following five years at Bayer Healthcare Diagnostics since 2017.
| Age | 60 |
| Tenure | 7 years |
| Address | 3950 South Country Club Road, Tucson, AZ, United States, 85714 |
| Phone | 520 365 3100 |
| Web | https://acceleratediagnostics.com |
Accelerate Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.7585) % which means that it has lost $0.7585 on every $100 spent on assets. This is way below average. Accelerate Diagnostics' management efficiency ratios could be used to measure how well Accelerate Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.25 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (1.87). At this time, Accelerate Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.4 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| William Haydon | Avanos Medical | 57 | |
| Jon Serbousek | Orthofix Medical | 63 | |
| Todd Garner | CONMED | 55 | |
| Kimberley Elting | Orthofix Medical | 59 | |
| Gregory Odle | Orthopediatrics Corp | 54 | |
| Paul Buckman | LivaNova PLC | 68 | |
| Michael Greiner | Avanos Medical | 51 | |
| Tom Thomas | Integer Holdings Corp | 53 | |
| Payman Khales | Integer Holdings Corp | 54 | |
| Stephanie Bolton | LivaNova PLC | 42 | |
| Erick DeVinney | Axogen Inc | 48 | |
| Kirk Thor | Integer Holdings Corp | 60 | |
| Johonna Pelletier | CONMED | 51 | |
| Heather Cohen | CONMED | 51 | |
| Tyler Lipschultz | Orthofix Medical | 57 | |
| Peter Shagory | CONMED | 55 | |
| Daniel Jonas | CONMED | 56 | |
| Stanley III | CONMED | 49 | |
| Daniel Gerritzen | Orthopediatrics Corp | 54 | |
| James Cunniff | Electromed | 58 | |
| Jason Garland | Integer Holdings Corp | 50 | |
Management Performance
| Return On Asset | -0.76 |
Accelerate Diagnostics Leadership Team
Elected by the shareholders, the Accelerate Diagnostics' board of directors comprises two types of representatives: Accelerate Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Accelerate. The board's role is to monitor Accelerate Diagnostics' management team and ensure that shareholders' interests are well served. Accelerate Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Accelerate Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lawrence Mertz, Chief Officer | ||
| Michael Bridge, Gen VP | ||
| Laura Costa, VP Support | ||
| Rita Boukamel, Senior EMEA | ||
| Jack Phillips, President CEO | ||
| Maya Gowri, Senior Operations | ||
| Ron Price, Senior Vice President Head - Commercial Operations | ||
| Cherif Bousselham, VP EMEA | ||
| Chris Thode, Senior Commercial | ||
| Steve Reichling, CFO, Chief Accounting Officer and Secretary | ||
| Gretchen Strohminger, Senior Culture | ||
| John Meduri, Chief Officer | ||
| Laura Pierson, Investor Officer | ||
| David Patience, Principal CFO |
Accelerate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Accelerate Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.88) % | ||||
| Current Valuation | 79.13 M | ||||
| Shares Outstanding | 25.04 M | ||||
| Shares Owned By Insiders | 40.60 % | ||||
| Shares Owned By Institutions | 17.45 % | ||||
| Number Of Shares Shorted | 510.51 K | ||||
| Price To Earning | (15.18) X | ||||
| Price To Sales | 3.36 X | ||||
| Revenue | 12.06 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.